The preferential interaction of CAR-NK92-derived exosomes with Her2-expressing tumor cells highlights their potential as a cell-free therapeutic modality that can complement or extend the cytotoxic activity of CAR-NK cells. The gene discussed is ERBB2; the disease is neoplasm.